Top

Published in:

01-01-2009 | Original Article

The Effect of iNOS Inhibitors and Hyperbaric Oxygen Treatment in a Rat Model of Experimental Colitis

Authors: Cemal Nuri Ercin, Zeki Yesilova, Ahmet Korkmaz, Ayhan Ozcan, Cagatay Oktenli, Ahmet Uygun

Published in: Digestive Diseases and Sciences | Issue 1/2009

Abstract

Aim Our aim was to investigate the effectiveness of aminoguanidine (AMG), an inducible nitric oxide synthase inhibitor, and hyperbaric oxygen (HBO) treatment in an experimental colitis model. Methods We induced colitis in rats. In the control group, we applied 2 ml serum physiologic intraperitoneally for 7 days. In the HBO group, 100% oxygen at 2.4 atm pressure was applied for 7 days. In the AMG group, 100 mg/kg AMG was applied intraperitoneally for 7 days. In the HBO + AMG group, HBO and AMG were applied, respectively. At the end of 7 days, rats were sacrificed and the distal 10 cm part of colon was examined macro- and microscopically. Results Severity of colitis and NO activities were reduced by AMG, HBO, and HBO + AMG application. There was histologically significant improvement, especially in the HBO + AMG group Conclusions Both HBO and AMG were significantly effective in preventing weight loss, reducing NO activities, and severity of colitis, when comparing HBO and AMG separately.

Pettersson S. Introduction: Inflammatory bowel disease: A complex systemic disease engaging multiple players outside the immune system. J Intern Med. 2008;263:574–576. doi:10.1111/j.1365-2796.2008.01973.x.PubMedCrossRef

Pavlick KP, Laroux FS, Fuseler J, et al. Role of reactive metabolities of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med. 2002;33:311–322. doi:10.1016/S0891-5849(02)00853-5.PubMedCrossRef

Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet. 1994;344:859–861. doi:10.1016/S0140-6736(94)92831-2.PubMedCrossRef

Harris ML, Schiller HJ, Reilly PM, Donowitz M, Grisham MB, Bulkley GB. Free radicals and other reactive oxygen metabolities in inflammatory bowel disease: Cause, consequence or epiphenomenon? Pharmacol Ther. 1992;53:375–408. doi:10.1016/0163-7258(92)90057-7.PubMedCrossRef

Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:179–189. doi:10.1097/00054725-200305000-00006.PubMedCrossRef

Singer II, Kawka DW, Scott S, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology. 1996;111:871–875. doi:10.1016/S0016-5085(96)70055-0.PubMedCrossRef

Grisham MB, Specian RD, Zimmerman TE. Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis. J Pharmacol Exp Ther. 1994;271:1114–1121.PubMed

Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut. 1995;37:247–255. doi:10.1136/gut.37.2.247.PubMedCrossRef

Rachmilewitz D, Karmeli F, Okon E. Sulfhydryl blocker-induced rat colonic inflammation is ameliorated by inhibition of nitric oxide synthase. Gastroenterology. 1995;109:98–106. doi:10.1016/0016-5085(95)90273-2.PubMedCrossRef

10.

Grim PS, Gottlieb LJ, Boddie A, Batson E. Hyperbaric oxygen therapy. JAMA. 1990;263:2216–2220. doi:10.1001/jama.263.16.2216.PubMedCrossRef

11.

Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S. Hyperbaric oxygen for perianal Crohn’s disease. J Clin Gastroenterol. 1994;19:202–205. doi:10.1097/00004836-199410000-00006.PubMedCrossRef

12.

Rachmilewitz D, Karmeli F, Okon E, Rubenstein I, Better OS. Hyperbaric oxygen: A novel modality to ameliorate experimental colitis. Gut. 1998;43:512–518.PubMedCrossRef

13.

Colombel JF, Mathieu D, Bouault JM, et al. Hyperbaric oxygenation in severe perineal Crohn’s disease. Dis Colon Rectum. 1995;38:609–614. doi:10.1007/BF02054120.PubMedCrossRef

14.

Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004;50:81–92. doi:10.1016/j.vascn.2003.12.002.PubMedCrossRef

15.

Yuan H, Ji WS, Wu KX, Jiao JX, Sun LH, Feng YT. Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol. 2006;12:4578–4581.PubMed

16.

Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: Appraisal of the Griess reaction in the l-arginine/nitric oxide area of research. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:51–70. doi:10.1016/j.jchromb.2006.07.054.PubMedCrossRef

17.

Butler AR, Flitney FW, Williams DL. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist’s perspective. Trends Pharmacol Sci. 1995;16:18–22. doi:10.1016/S0165-6147(00)88968-3.PubMedCrossRef

18.

Takahashı T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J Gastroenterol. 2003;38:421–430. doi:10.1007/s00535-003-1094-y.PubMedCrossRef

19.

Cuzzocrea S, McDonald MC, Mazzon E, et al. Tempol, a membrane-permeable radical scavenger, reduces dinitrobenzene sulfonic acid-induced colitis. Eur J Pharmacol. 2000;406:127–137. doi:10.1016/S0014-2999(00)00623-3.PubMedCrossRef

20.

Zingarelli B, Cuzzocrea S, Szabo C, Salzman AL. Mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther. 1998;287:1048–1055.PubMed

21.

Roediger WE, Lawson MJ, Nance SH, Radcliffe BC. Detectable colonic nitrite levels in inflammatory bowel disease-mucosal or bacterial mulfunction? Digestion. 1986;35:199–204.PubMedCrossRef

22.

Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet. 1993;341:465–466. doi:10.1016/0140-6736(93)90211-X.PubMedCrossRef

23.

Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. Gut. 1995;36:718–723. doi:10.1136/gut.36.5.718.PubMedCrossRef

24.

Rachmilewitz D, Eliakim R, Ackerman Z, Karmeli F. Direct determination of colonic nitric oxide level—a sensitive marker of disease activity in ulcerative colitis. Am J Gastroenterol. 1998;93:409–412.PubMed

25.

Hogaboam CM, Jacobson K, Collins SM, Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol. 1995;268:G673–G684.PubMed

26.

Perner A, Andresen L, Normark M, et al. Expression of nitric oxide synthases and effects of L-arginine and L-NMMA on nitric oxide production and fluid transport in collagenous colitis. Gut. 2001;49:387–394. doi:10.1136/gut.49.3.387.PubMedCrossRef

27.

Kankuri E, Hamalainen M, Hukkanen M, et al. Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis. Scand J Gastroenterol. 2003;38:186–192. doi:10.1080/00365520310000681.PubMedCrossRef

28.

Pilichos CJ, Kouerinis IA, Zografos GC, et al. The effect of nitric oxide synthases inhibitors on inflammatory bowel disease in a rat model. In Vivo. 2004;18:513–516.PubMed

29.

Dudhgaonkar SP, Tandan SK, Kumar D, Raviprakash V, Kataria M. Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats. Inflammopharmacol. 2007;15:188–195. doi:10.1007/s10787-007-1603-3.CrossRef

30.

Nakamura H, Tsukada H, Oya M, et al. Aminoguanidine has both an anti-inflammatory effect on experimental colitis and a proliferative effect on colonic mucosal cells. Scand J Gastroenterol. 1999;34:1117–1122. doi:10.1080/003655299750024922.PubMedCrossRef

31.

Cuthbertson CM, Christophi C. Potential effects of hyperbaric oxygen therapy in acute pancreatitis. ANZ J Surg. 2006;76:625–630. doi:10.1111/j.1445-2197.2006.03793.x.PubMedCrossRef

32.

Christophi C, Millar I, Nikfarjam M, Muralidharan V, Malcontenti-Wilson C. Hyperbaric oxygen therapy for severe acute pancreatitis. J Gastroenterol Hepatol. 2007;22:2042–2046. doi:10.1111/j.1440-1746.2006.03380.x.PubMedCrossRef

33.

Alex J, Laden G, Cale AR, et al. Pretreatment with hyperbaric oxygen and its effect on neuropsychometric dysfunction and systemic inflammatory response after cardiopulmonary bypass: A prospective randomized double-blind trial. J Thorac Cardiovasc Surg. 2005;130:1623–1630. doi:10.1016/j.jtcvs.2005.08.018.PubMedCrossRef

34.

Marshall GT, Thirlby RC, Bredfeldt JE, Hampson NB. Treatment of gastrointestinal radiation injury with hyperbaric oxygen. Undersea Hyperb Med. 2007;34:35–42.PubMed

35.

Filntisis GA, Moon RE, Kraft KL, Farmer JC, Scher RL, Piantadosi CA. Laryngeal radionecrosis and hyperbaric oxygen therapy: Report of 18 cases and review of the literature. Ann Otol Rhinol Laryngol. 2000;109:554–562.PubMed

36.

Gürbüz AK, Elbüken E, Yazgan Y, Yildiz S. A different therapeutic approach in patients with severe ulcerative colitis: Hyperbaric oxygen treatment. South Med J. 2003;96:632–633. doi:10.1097/01.SMJ.0000074507.31006.79.PubMedCrossRef

37.

Gorgulu S, Yagci G, Kaymakcioglu N, et al. Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats. Dig Dis Sci. 2006;51:480–487. doi:10.1007/s10620-006-3159-2.PubMedCrossRef

38.

Demirtürk L, Ozel M, Yazgan Y, Buchman AL. Therapeutic efficacy of hyperbaric oxygenation in ulcerative colitis refractory to medical treatment. J Clin Gastroenterol. 2002;35:286–287. doi:10.1097/00004836-200209000-00021.PubMedCrossRef

39.

Buchman AL, Fife C, Torres C, Smith L, Aristizibal J. Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol. 2001;33:337–339. doi:10.1097/00004836-200110000-00018.PubMedCrossRef

40.

Gulec B, Yasar M, Yildiz S, et al. Effect of hyperbaric oxygen on experimental acute distal colitis. Physiol Res. 2004;53:493–499.PubMed

41.

Atug O, Hamzaoglu H, Tahan V, et al. Hyperbaric oxygen therapy is as effective as dexamethasone in the treatment of TNBS-E-induced experimental colitis. Dig Dis Sci. 2008;53:481–485. doi:10.1007/s10620-007-9956-4.PubMedCrossRef

42.

Akin ML, Gulluoglu BM, Uluutku H, et al. Hyperbaric oxygen improves healing in experimental rat colitis. Undersea Hyperb Med. 2002;29:279–285.PubMed

43.

Lin HC, Wan FJ, Wu CC, Tung CS, Wu TH. Hyperbaric oxygen protects against lipopolysaccharide-stimulated oxidative stress and mortality in rats. Eur J Pharmacol. 2005;508:249–254. doi:10.1016/j.ejphar.2004.12.021.PubMedCrossRef

Title: The Effect of iNOS Inhibitors and Hyperbaric Oxygen Treatment in a Rat Model of Experimental Colitis
Authors: Cemal Nuri Ercin
Zeki Yesilova
Ahmet Korkmaz
Ayhan Ozcan
Cagatay Oktenli
Ahmet Uygun
Publication date: 01-01-2009
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 1/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0498-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Digestive Diseases and Sciences—Past, Present, and Future

Peptides Derived from a Soluble Molecule of the Human Leukocyte Antigen (HLA) Class I Cause Apoptosis in Gastric Cancer Cell Lines

Symptomatic Multichannel Pylorus as a Complication of Previous Peptic Ulcer Surgery

Adrenomedullin as Preventive Treatment in Cerulein-induced Acute Pancreatitis

Aspirin-Induced Mucosal Cell Death in Human Gastric Cells: Role of a Caspase-Independent Mechanism

Effect of Music on Patients Undergoing Colonoscopy: A Meta-Analysis of Randomized Controlled Trials

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials